EpCAM-targeted betulinic acid analogue nanotherapy improves therapeutic efficacy and induces anti-tumorigenic immune response in colorectal cancer tumor microenvironment.
Aptamer
Betulinic acid analogue
Colorectal cancer
EpCAM
Immune response
Tumor-microenvironment
Journal
Journal of biomedical science
ISSN: 1423-0127
Titre abrégé: J Biomed Sci
Pays: England
ID NLM: 9421567
Informations de publication
Date de publication:
20 Aug 2024
20 Aug 2024
Historique:
received:
20
12
2023
accepted:
09
07
2024
medline:
21
8
2024
pubmed:
21
8
2024
entrez:
20
8
2024
Statut:
epublish
Résumé
Betulinic acid (BA) has been well investigated for its antiproliferative and mitochondrial pathway-mediated apoptosis-inducing effects on various cancers. However, its poor solubility and off-target activity have limited its utility in clinical trials. Additionally, the immune modulatory role of betulinic acid analogue in the tumor microenvironment (TME) is largely unknown. Here, we designed a potential nanotherapy for colorectal cancer (CRC) with a lead betulinic acid analogue, named as 2c, carrying a 1,2,3-triazole-moiety attached to BA through a linker, found more effective than BA for inhibiting CRC cell lines, and was chosen here for this investigation. Epithelial cell adhesion molecule (EpCAM) is highly overexpressed on the CRC cell membrane. A single-stranded short oligonucleotide sequence, aptamer (Apt), that folds into a 3D-defined architecture can be used as a targeting ligand for its specific binding to a target protein. EpCAM targeting aptamer was designed for site-specific homing of aptamer-conjugated-2c-loaded nanoparticles (Apt-2cNP) at the CRC tumor site to enhance therapeutic potential and reduce off-target toxicity in normal cells. We investigated the in vitro and in vivo therapeutic efficacy and anti-tumorigenic immune response of aptamer conjugated nanotherapy in CRC-TME. After the characterization of nanoengineered aptamer conjugated betulinic acid nanotherapy, we evaluated therapeutic efficacy, tumor targeting efficiency, and anti-tumorigenic immune response using cell-based assays and mouse and rat models. We found that Apt-2cNP improved drug bioavailability, enhanced its biological half-life, improved antiproliferative activity, and minimized off-target cytotoxicity. Importantly, in an in vivo TME, Apt-2cNP showed promising signs of anti-tumorigenic immune response (increased mDC/pDC ratio, enhanced M1 macrophage population, and CD8 T-cells). Furthermore, in vivo upregulation of pro-apoptotic while downregulation of anti-apoptotic genes and significant healing efficacy on cancer tissue histopathology suggest that Apt-2cNP had predominantly greater therapeutic potential than the non-aptamer-conjugated nanoparticles and free drug. Moreover, we observed greater tumor accumulation of the radiolabeled Apt-2cNP by live imaging in the CRC rat model. Enhanced therapeutic efficacy and robust anti-tumorigenic immune response of Apt-2cNP in the CRC-TME are promising indicators of its potential as a prospective therapeutic agent for managing CRC. However, further studies are warranted.
Sections du résumé
BACKGROUND
BACKGROUND
Betulinic acid (BA) has been well investigated for its antiproliferative and mitochondrial pathway-mediated apoptosis-inducing effects on various cancers. However, its poor solubility and off-target activity have limited its utility in clinical trials. Additionally, the immune modulatory role of betulinic acid analogue in the tumor microenvironment (TME) is largely unknown. Here, we designed a potential nanotherapy for colorectal cancer (CRC) with a lead betulinic acid analogue, named as 2c, carrying a 1,2,3-triazole-moiety attached to BA through a linker, found more effective than BA for inhibiting CRC cell lines, and was chosen here for this investigation. Epithelial cell adhesion molecule (EpCAM) is highly overexpressed on the CRC cell membrane. A single-stranded short oligonucleotide sequence, aptamer (Apt), that folds into a 3D-defined architecture can be used as a targeting ligand for its specific binding to a target protein. EpCAM targeting aptamer was designed for site-specific homing of aptamer-conjugated-2c-loaded nanoparticles (Apt-2cNP) at the CRC tumor site to enhance therapeutic potential and reduce off-target toxicity in normal cells. We investigated the in vitro and in vivo therapeutic efficacy and anti-tumorigenic immune response of aptamer conjugated nanotherapy in CRC-TME.
METHODS
METHODS
After the characterization of nanoengineered aptamer conjugated betulinic acid nanotherapy, we evaluated therapeutic efficacy, tumor targeting efficiency, and anti-tumorigenic immune response using cell-based assays and mouse and rat models.
RESULTS
RESULTS
We found that Apt-2cNP improved drug bioavailability, enhanced its biological half-life, improved antiproliferative activity, and minimized off-target cytotoxicity. Importantly, in an in vivo TME, Apt-2cNP showed promising signs of anti-tumorigenic immune response (increased mDC/pDC ratio, enhanced M1 macrophage population, and CD8 T-cells). Furthermore, in vivo upregulation of pro-apoptotic while downregulation of anti-apoptotic genes and significant healing efficacy on cancer tissue histopathology suggest that Apt-2cNP had predominantly greater therapeutic potential than the non-aptamer-conjugated nanoparticles and free drug. Moreover, we observed greater tumor accumulation of the radiolabeled Apt-2cNP by live imaging in the CRC rat model.
CONCLUSIONS
CONCLUSIONS
Enhanced therapeutic efficacy and robust anti-tumorigenic immune response of Apt-2cNP in the CRC-TME are promising indicators of its potential as a prospective therapeutic agent for managing CRC. However, further studies are warranted.
Identifiants
pubmed: 39164686
doi: 10.1186/s12929-024-01069-8
pii: 10.1186/s12929-024-01069-8
doi:
Substances chimiques
Betulinic Acid
4G6A18707N
Pentacyclic Triterpenes
0
Epithelial Cell Adhesion Molecule
0
EPCAM protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
81Subventions
Organisme : Department of Biotechnology, Govt. of India
ID : DBT/RA/16/05/2016
Informations de copyright
© 2024. The Author(s).
Références
Betulinic Acid Triggers CD95 (APO-1/Fas)- and p53-independent Apoptosis via Activation of Caspases in Neuroectodermal Tumors1|Cancer Research|American Association for Cancer Research. [cited 2022 Sep 18]. Available from: https://aacrjournals.org/cancerres/article/57/21/4956/503713/Betulinic-Acid-Triggers-CD95-APO-1-Fas-and-p53 .
Fulda S, Scaffidi G, Susin SA, Krammer PH, Kroemer G, Peter ME, et al. Activation of mitochondria and release of mitochondrial apoptogenic factors by betulinic acid. J Biol Chem. 1998;273:33942–8.
pubmed: 9852046
doi: 10.1074/jbc.273.51.33942
Wick W, Grimmel C, Wagenknecht B, Dichgans J, Weller M. Betulinic acid-induced apoptosis in glioma cells: a sequential requirement for new protein synthesis, formation of reactive oxygen species, and caspase processing. J Pharmacol Exp Ther. 1999;289:1306.
pubmed: 10336521
Zuco V, Supino R, Righetti SC, Cleris L, Marchesi E, Gambacorti-Passerini C, et al. Selective cytotoxicity of betulinic acid on tumor cell lines, but not on normal cells. Cancer Lett. 2002;175:17–25.
pubmed: 11734332
doi: 10.1016/S0304-3835(01)00718-2
Ji ZN, Ye WC, Liu GG, Hsiao WLW. 23-Hydroxybetulinic acid-mediated apoptosis is accompanied by decreases in bcl-2 expression and telomerase activity in HL-60 Cells. Life Sci. 2002;72:1–9.
pubmed: 12409140
doi: 10.1016/S0024-3205(02)02176-8
Thurnher D, Turhani D, Pelzmann M, Wannemacher B, Knerer B, Formanek M, et al. Betulinic acid: a new cytotoxic compound against malignant head and neck cancer cells. Head Neck. 2003;25:732–40.
pubmed: 12953308
doi: 10.1002/hed.10231
Dutta D, Paul B, Mukherjee B, Mondal L, Sen S, Chowdhury C, et al. Nanoencapsulated betulinic acid analogue distinctively improves colorectal carcinoma in vitro and in vivo. Sci Rep. 2019;9:11506.
pubmed: 31395908
pmcid: 6687831
doi: 10.1038/s41598-019-47743-y
Mir M, Ahmed N, Rehman A. Recent applications of PLGA based nanostructures in drug delivery. Colloids Surf B Biointerfaces. 2017;159:217–31.
pubmed: 28797972
doi: 10.1016/j.colsurfb.2017.07.038
Hans ML, Lowman AM. Biodegradable nanoparticles for drug delivery and targeting. Curr Opin Solid State Mater Sci. 2002;6:319–27.
doi: 10.1016/S1359-0286(02)00117-1
Punfa W, Yodkeeree S, Pitchakarn P, Ampasavate C, Limtrakul P. Enhancement of cellular uptake and cytotoxicity of curcumin-loaded PLGA nanoparticles by conjugation with anti-P-glycoprotein in drug resistance cancer cells. Acta Pharmacol Sin. 2012;33:823–31.
pubmed: 22580738
pmcid: 4010380
doi: 10.1038/aps.2012.34
Makadia HK, Siegel SJ. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymer. 2011;3:1377–97.
doi: 10.3390/polym3031377
Mondal L, Mukherjee B, Das K, Bhattacharya S, Dutta D, Chakraborty S, et al. CD-340 functionalized doxorubicin-loaded nanoparticle induces apoptosis and reduces tumor volume along with drug-related cardiotoxicity in mice. Int J Nanomed. 2019;14:8073.
doi: 10.2147/IJN.S220740
Wang J, Li Y, Nie G. Multifunctional biomolecule nanostructures for cancer therapy. Nat Rev Mater. 2021;6:766–83.
pubmed: 34026278
pmcid: 8132739
doi: 10.1038/s41578-021-00315-x
Kim HW, Chung CW, Kim YB, Rhee YH. Preparation and hydrolytic degradation of semi-interpenetrating networks of poly(3-hydroxyundecenoate) and poly(lactide-co-glycolide). Int J Biol Macromol. 2005;37:221–6.
pubmed: 16405991
doi: 10.1016/j.ijbiomac.2005.11.002
Mukherjee B, Roy G, Santra K, Sahana B. Lactide-glycolide polymers as nano-dimensional carriers for drugs. Int J Biomed Nanosci Nanotechnol. 2010;1:230–46.
doi: 10.1504/IJBNN.2010.034653
Zhao N, Ge Y, Chiao PJ, Zu Y. Development and characterization of a ssDNA-based aptamer that selectively targets epithelial carcinoma cells. J Mol Biomark Diagn. 2014;05.
Bhattacharya S, Mondal L, Mukherjee B, Dutta L, Ehsan I, Debnath MC, et al. Apigenin loaded nanoparticle delayed development of hepatocellular carcinoma in rats. Nanomedicine. 2018;14:1905–17.
pubmed: 29802937
doi: 10.1016/j.nano.2018.05.011
Adachi T, Nakamura Y. Aptamers: a review of their chemical properties and modifications for therapeutic application. Molecules. 2019;24:4229.
pubmed: 31766318
pmcid: 6930564
doi: 10.3390/molecules24234229
Zhao L, Zhang B. Doxorubicin induces cardiotoxicity through upregulation of death receptors mediated apoptosis in cardiomyocytes. Sci Rep. 2017;7:1–11.
Hazra RS, Kale N, Aland G, Qayyumi B, Mitra D, Jiang L, et al. Cellulose mediated transferrin nanocages for enumeration of circulating tumor cells for head and neck cancer. Sci Rep. 2020;10:1–14.
RCSB PDB-1A36: TOPOISOMERASE I/DNA COMPLEX. Available from: https://www.rcsb.org/structure/1a36 .
RCSB PDB-2RGR: Topoisomerase IIA bound to G-segment DNA. Available from: https://www.rcsb.org/structure/2rgr .
Gaussian 09 Citation | Gaussian.com. Available from: https://gaussian.com/g09citation/ .
Morris GM, Ruth H, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem. 2009;30:2785–91.
pubmed: 19399780
pmcid: 2760638
doi: 10.1002/jcc.21256
Yang Z, Lasker K, Schneidman-Duhovny D, Webb B, Huang CC, Pettersen EF, et al. UCSF Chimera, MODELLER, and IMP: an integrated modeling system. J Struct Biol. 2012;179:269–78.
pubmed: 21963794
doi: 10.1016/j.jsb.2011.09.006
Yan Y, Tao H, He J, Huang SY. The HDOCK server for integrated protein–protein docking. Nat Protoc. 2020;15:1829–52.
pubmed: 32269383
doi: 10.1038/s41596-020-0312-x
BIOVIA Discovery Studio-BIOVIA-Dassault Systèmes
Fan L, Campagnoli S, Wu H, Grandi A, Parri M, De Camilli E, et al. Negatively charged AuNP modified with monoclonal antibody against novel tumor antigen FAT1 for tumor targeting. J Exp Clin Cancer Res. 2015;34:1–13.
doi: 10.1186/s13046-015-0214-x
Paul B, Gaonkar RH, Mukhopadhyay R, Ganguly S, Debnath MC, Mukherjee B. Garcinol-loaded novel cationic nanoliposomes: in vitro and in vivo study against B16F10 melanoma tumor model. Nanomedicine (London). 2019;14:2045–65.
doi: 10.2217/nnm-2019-0022
Valero T, Delgado-González A, Unciti-Broceta JD, Cano-Cortés V, Pérez-López AM, Unciti-Broceta A, et al. Drug “clicking” on cell-penetrating fluorescent nanoparticles for in cellulo chemical proteomics. Bioconjug Chem. 2018;29:3154–60. https://doi.org/10.1021/acs.bioconjchem.8b00481 .
doi: 10.1021/acs.bioconjchem.8b00481
pubmed: 30122043
Logue SE, Elgendy M, Martin SJ. Expression, purification and use of recombinant annexin V for the detection of apoptotic cells. Nat Protoc. 2009;4:1383–95.
pubmed: 19730422
doi: 10.1038/nprot.2009.143
Barnum KJ, O’Connell MJ. Cell cycle regulation by checkpoints. Methods Mol Biol. 2014;1170:29–40. https://doi.org/10.1007/978-1-4939-0888-2_2 .
doi: 10.1007/978-1-4939-0888-2_2
pubmed: 24906307
pmcid: 4990352
Franken NAP, Rodermond HM, Stap J, Haveman J, van Bree C. Clonogenic assay of cells in vitro. Nat Protoc. 2006;1:2315–9.
pubmed: 17406473
doi: 10.1038/nprot.2006.339
Murthy D, Dutta D, Attri KS, Samanta T, Yang S, Jung KH, et al. CD24 negativity reprograms mitochondrial metabolism to PPARα and NF-κB-driven fatty acid β-oxidation in triple-negative breast cancer. Cancer Lett. 2024;587:216724.
pubmed: 38373689
pmcid: 11068061
doi: 10.1016/j.canlet.2024.216724
Dutta D, Liu J, Wen K, Kurata K, Fulciniti M, Gulla A, et al. BCMA-targeted bortezomib nanotherapy improves therapeutic efficacy, overcomes resistance, and modulates the immune microenvironment in multiple myeloma. Blood Cancer J. 2023;13:1–13.
doi: 10.1038/s41408-023-00955-y
Al Hoque A, Dutta D, Paul B, Kumari L, Ehsan I, Dhara M, et al. ΔPSap4#5 surface-functionalized abiraterone-loaded nanoparticle successfully inhibits carcinogen-induced prostate cancer in mice: a mechanistic investigation. Cancer Nanotechnol. 2023;14:1–34. https://doi.org/10.1186/s12645-023-00223-5 .
doi: 10.1186/s12645-023-00223-5
Kumari L, Ehsan I, Mondal A, Al Hoque A, Mukherjee B, Choudhury P, et al. Cetuximab-conjugated PLGA nanoparticles as a prospective targeting therapeutics for non-small cell lung cancer. J Drug Target. 2023. https://doi.org/10.1080/1061186X.2023.2199350 .
doi: 10.1080/1061186X.2023.2199350
pubmed: 37539789
Mukherjee B, Mayer D. Dihydrotestosterone interacts with EGFR/MAPK signalling and modulates EGFR levels in androgen receptor-positive LNCaP prostate cancer cells. Int J Oncol. 2008;33:623–9. https://doi.org/10.3892/ijo_00000048/abstract .
doi: 10.3892/ijo_00000048/abstract
pubmed: 18695894
Dutta D, Chakraborty A, Mukherjee B, Gupta S. Aptamer-conjugated apigenin nanoparticles to target colorectal carcinoma: a promising safe alternative of colorectal cancer chemotherapy. ACS Appl Bio Mater. 2018;1:1538–56.
pubmed: 34996205
doi: 10.1021/acsabm.8b00441
Sen R, Mukherjee B, Ganguly S, Sinha S. Surface-functionalized luteolin-loaded nanocarriers successfully delayed lung cancer progress in rats. J Mater Sci. 2023;58:7731–57. https://doi.org/10.1007/s10853-023-08490-8 .
doi: 10.1007/s10853-023-08490-8
Dhara M, AlHoque A, Sen R, Dutta D, Mukherjee B, Paul B, et al. Phosphorothioated amino-AS1411 aptamer functionalized stealth nanoliposome accelerates bio-therapeutic threshold of apigenin in neoplastic rat liver: a mechanistic approach. J Nanobiotechnol. 2023;21:28.
doi: 10.1186/s12951-022-01764-4
Dutta L, Mukherjee B, Chakraborty T, Das MK, Mondal L, Bhattacharya S, Gaonkar RH, Debnath MC. Lipid-based nanocarrier efficiently delivers highly water soluble drug across the blood–brain barrier into brain. Drug Deliv. 2018;25(1):504–16. https://doi.org/10.1080/10717544.2018.1435749 .
doi: 10.1080/10717544.2018.1435749
pubmed: 29426257
pmcid: 6058568
Alshaer W, Ababneh N, Hatmal M, Izmirli H, Choukeife M, Shraim A, et al. Selection and targeting of EpCAM protein by ssDNA aptamer. PLoS ONE. 2017;12:e0189558. https://doi.org/10.1371/journal.pone.0189558 .
doi: 10.1371/journal.pone.0189558
pubmed: 29245156
pmcid: 5731996
Chakraborty S, Dlie ZY, Chakraborty S, Roy S, Mukherjee B, Besra SE, et al. Aptamer-functionalized drug nanocarrier improves hepatocellular carcinoma toward normal by targeting neoplastic hepatocytes. Mol Ther Nucleic Acids Cell Press. 2020;20:34–49.
doi: 10.1016/j.omtn.2020.01.034
Medley CD, Bamrungsap S, Tan W, Smith JE. Aptamer-conjugated nanoparticles for cancer cell detection. Anal Chem. 2011;83:727–34.
pubmed: 21218774
pmcid: 3059367
doi: 10.1021/ac102263v
Chakraborty B, Dutta D, Mukherjee S, Das S, Maiti NC, Das P, et al. Synthesis and biological evaluation of a novel betulinic acid derivative as an inducer of apoptosis in human colon carcinoma cells (HT-29). Eur J Med Chem. 2015;102:93–105.
pubmed: 26248310
doi: 10.1016/j.ejmech.2015.07.035
SenthilKumar G, Skiba JH, Kimple RJ. High-throughput quantitative detection of basal autophagy and autophagic flux using image cytometry. Biotechniques. 2019;67:70–3.
pubmed: 31238709
pmcid: 7141596
doi: 10.2144/btn-2019-0044
P Sharma O. Clinical biochemistry of hepatotoxicity. J Clin Toxicol. 2014;04.
Tsoi MF, Cheung CL, Cheung TT, Cheung BMY. Continual decrease in blood lead level in Americans: United States National Health Nutrition and Examination Survey 1999–2014. Am J Med. 2016;129:1213–8. https://doi.org/10.1016/j.amjmed.2016.05.042 .
doi: 10.1016/j.amjmed.2016.05.042
pubmed: 27341956
Banushi B, Joseph SR, Lum B, Lee JJ, Simpson F. Endocytosis in cancer and cancer therapy. Nat Rev Cancer. 2023;23:450–73.
pubmed: 37217781
doi: 10.1038/s41568-023-00574-6
Varkouhi AK, Scholte M, Storm G, Haisma HJ. Endosomal escape pathways for delivery of biologicals. J Control Release. 2011;151:220–8.
pubmed: 21078351
doi: 10.1016/j.jconrel.2010.11.004
Baboci L, Capolla S, Di Cintio F, Colombo F, Mauro P, Dal Bo M, et al. The dual role of the liver in nanomedicine as an actor in the elimination of nanostructures or a therapeutic target. J Oncol. 2020;2020:1–15.
doi: 10.1155/2020/4638192
Perše M, Cerar A. Morphological and molecular alterations in 1,2 dimethylhydrazine and azoxymethane induced colon carcinogenesis in rats. J Biomed Biotechnol. 2011;2011:473964.
pubmed: 21253581
Youssef KM, Ezzo AM, El-Sayed MI, Hazzaa AA, EL-Medany AH, Arafa M. Chemopreventive effects of curcumin analogs in DMH-Induced colon cancer in albino rats model. Futur J Pharm Sci. 2015;1:57–72.
Singh R, Lillard JW. Nanoparticle-based targeted drug delivery. Exp Mol Pathol. 2009;86:215.
pubmed: 19186176
pmcid: 3249419
doi: 10.1016/j.yexmp.2008.12.004
Chen B, Yang JZ, Wang LF, Zhang YJ, Lin XJ. Ifosfamide-loaded poly (lactic-co-glycolic acid) PLGA-dextran polymeric nanoparticles to improve the antitumor efficacy in Osteosarcoma. BMC Cancer. 2015;15:1–9. https://doi.org/10.1186/s12885-015-1735-6 .
doi: 10.1186/s12885-015-1735-6
Wallace SJ, Li J, Nation RL, Boyd BJ. Drug release from nanomedicines: selection of appropriate encapsulation and release methodology. Drug Deliv Transl Res. 2012;2:284–92.
pubmed: 23110256
pmcid: 3482165
doi: 10.1007/s13346-012-0064-4
Tannock IF, Rotin D. Acid pH in Tumors and its potential for therapeutic exploitation. Cancer Res. 1989;49:4373–84.
pubmed: 2545340
Pattnaik G, Sinha B, Mukherjee B, Ghosh S, Basak S, Mondal S, et al. Submicron-size biodegradable polymer-based didanosine particles for treating HIV at early stage: an in vitro study. J Microencapsul. 2012;29:666–76.
pubmed: 22545676
doi: 10.3109/02652048.2012.680509
Higuchi T. Mechanism of sustained-action medication. J Pharm Sci. 1963;52:1145–9.
pubmed: 14088963
doi: 10.1002/jps.2600521210
Dutta D, Chakraborty B, Sarkar A, Chowdhury C, Das P. A potent betulinic acid analogue ascertains an antagonistic mechanism between autophagy and proteasomal degradation pathway in HT-29 cells. BMC Cancer. 2016;16:1–19.
doi: 10.1186/s12885-016-2055-1
Abdurashidova G, Radulescu S, Sandoval O, Zahariev S, Danailov MB, Demidovich A, et al. Functional interactions of DNA topoisomerases with a human replication origin. EMBO J. 2007;26:998.
pubmed: 17290216
pmcid: 1852844
doi: 10.1038/sj.emboj.7601578
Wada SI, Tanaka R. Betulinic acid and its derivatives, potent DNA topoisomerase II inhibitors, from the Bark of Bischofia javanica. Chem Biodivers. 2005;2:689–94. https://doi.org/10.1002/cbdv.200590045 .
doi: 10.1002/cbdv.200590045
pubmed: 17192012
Mathiassen SG, De Zio D, Cecconi F. Autophagy and the cell cycle: acomplex landscape. Front Oncol. 2017;7:1–16.
doi: 10.3389/fonc.2017.00051
Chen ML, Lai CJ, Lin YN, Huang CM, Lin YH. Multifunctional nanoparticles for targeting the tumor microenvironment to improve synergistic drug combinations and cancer treatment effects. J Mater Chem B. 2020;8:10416–27.
pubmed: 33112350
doi: 10.1039/D0TB01733G
Hisamuddin IM, Yang VW. Molecular genetics of colorectal cancer: an overview. Curr Color Cancer Rep. 2006;2:53–9. https://doi.org/10.1007/s11888-006-0002-2 .
doi: 10.1007/s11888-006-0002-2
Ghodousi-Dehnavi E, Hosseini RH, Arjmand M, Nasri S, Zamani Z. A Metabolomic Investigation of Eugenol on Colorectal Cancer Cell Line HT-29 by Modifying the Expression of APC, p53, and KRAS Genes. Evidence-based Complement Altern Med Hindawi Limited. 2021;2021:1–9.
doi: 10.1155/2021/1448206
Oeckinghaus A, Ghosh S. The NF-κB family of transcription factors and its regulation. Cold Spring Harb Perspect Biol. 2009;1:a000034.
pubmed: 20066092
pmcid: 2773619
doi: 10.1101/cshperspect.a000034
Bracci L, Schiavoni G, Sistigu A, Belardelli F. Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ. 2014;21:15–25.
pubmed: 23787994
doi: 10.1038/cdd.2013.67
Park S, Kang S, Chen X, Kim EJ, Kim J, Kim N, et al. Tumor suppression via paclitaxel-loaded drug carriers that target inflammation marker upregulated in tumor vasculature and macrophages. Biomaterials. 2013;34:598–605. https://doi.org/10.1016/j.biomaterials.2012.10.004 .
doi: 10.1016/j.biomaterials.2012.10.004
pubmed: 23099063
Javeed A, Ashraf M, Riaz A, Ghafoor A, Afzal S, Mukhtar MM. Paclitaxel and immune system. Eur J Pharm Sci. 2009;38:283–90.
pubmed: 19733657
doi: 10.1016/j.ejps.2009.08.009
Liu P, Jaffar J, Hellstrom I, Hellstrom KE. Administration of cyclophosphamide changes the immune profile of tumor-bearing mice. J Immunother. 2010;33:53–9.
pubmed: 19952956
pmcid: 2811714
doi: 10.1097/CJI.0b013e3181b56af4
Doloff JC, Waxman DJ. VEGF receptor inhibitors block the ability of metronomically dosed cyclophosphamide to activate innate immunity-induced tumor regression. Cancer Res. 2012;72:1103–15.
pubmed: 22237627
pmcid: 3294103
doi: 10.1158/0008-5472.CAN-11-3380
Zafari N, Khosravi F, Rezaee Z, Esfandyari S, Bahiraei M, Bahramy A, et al. The role of the tumor microenvironment in colorectal cancer and the potential therapeutic approaches. J Clin Lab Anal. 2022;36:1–17.
doi: 10.1002/jcla.24585
Jangpatarapongsa K, Chootong P, Sattabongkot J, Chotivanich K, Sirichaisinthop J, Tungpradabkul S, et al. Plasmodium vivax parasites alter the balance of myeloid and plasmacytoid dendritic cells and the induction of regulatory T cells. Eur J Immunol. 2008;38:2697–705. https://doi.org/10.1002/eji.200838186 .
doi: 10.1002/eji.200838186
pubmed: 18825754
pmcid: 2757553
White E, Karp C, Strohecker AM, Guo Y, Mathew R. Role of autophagy in suppression of inflammation and cancer. Curr Opin Cell Biol. 2010;22:212–7.
pubmed: 20056400
pmcid: 2857707
doi: 10.1016/j.ceb.2009.12.008
Netea-Maier RT, Plantinga TS, van de Veerdonk FL, Smit JW, Netea MG. Modulation of inflammation by autophagy: consequences for human disease. Autophagy. 2016;12:245–60. https://doi.org/10.1080/15548627.2015.1071759 .
doi: 10.1080/15548627.2015.1071759
pubmed: 26222012
Jiang GM, Tan Y, Wang H, Peng L, Chen HT, Meng XJ, et al. The relationship between autophagy and the immune system and its applications for tumor immunotherapy. Mol Cancer. 2019;18:1–22. https://doi.org/10.1186/s12943-019-0944-z .
doi: 10.1186/s12943-019-0944-z
Chen C, Zhou S, Cai Y, Tang F. Nucleic acid aptamer application in diagnosis and therapy of colorectal cancer based on cell-SELEX technology. NPJ Precis Oncol. 2017;1:37.
pubmed: 29872716
pmcid: 5871892
doi: 10.1038/s41698-017-0041-y
Oh BY, Hong HK, Lee WY, Cho YB. Animal models of colorectal cancer with liver metastasis. Cancer Lett. 2017;387:114–20.
pubmed: 26850374
doi: 10.1016/j.canlet.2016.01.048
Mukherjee B, Basu M, Chatterjee M. Effect of selenomethionine on N-methylnitronitrosoguanidine-induced colonic aberrant crypt foci in rats. Eur J Cancer Prev. 2001;10:347–55.
pubmed: 11535877
doi: 10.1097/00008469-200108000-00008
Ma JC, Luo T, Feng B, Huang Z, Zhang Y, Huang H, et al. Exploring the translational potential of PLGA nanoparticles for intra-articular rapamycin delivery in osteoarthritis therapy. J Nanobiotechnol. 2023;21:1–18. https://doi.org/10.1186/s12951-023-02118-4 .
doi: 10.1186/s12951-023-02118-4